Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics在2024年第一季度結束時擁有11億美元的現金、現金等價物和有價證券；現金跑道預計將支持2027年的運營計劃
Beam Therapeutics Ended Q1 2024 With $1.1B In Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans Into 2027
Beam Therapeutics在2024年第一季度結束時擁有11億美元的現金、現金等價物和有價證券；現金跑道預計將支持2027年的運營計劃
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。